JNJ Factor-Based Stock Analysis

Johnson & Johnson (JNJ) has received an 88% rating from Validea's P/B Growth Investor model, based on Partha Mohanram's strategy, making it the highest-rated stock among 22 guru strategies. This model identifies low book-to-market stocks exhibiting characteristics for sustained future growth. As a large-cap growth stock in the Biotechnology & Drugs sector, JNJ's strong fundamental and valuation scores indicate significant interest, despite failing one criterion related to Research and Development to Assets within the model's framework.

Analysis

Johnson & Johnson (JNJ) scores an 88% rating from Validea's P/B Growth Investor model, placing it as the highest-rated security among 22 guru strategies. This academic-based model from Partha Mohanram identifies low book-to-market stocks with fundamental characteristics indicating sustained growth. JNJ, a large-cap in the Biotechnology & Drugs industry, passed eight distinct criteria, demonstrating notable strength in Return on Assets (ROA), Cash Flow from Operations to Assets, and low variance in both ROA and sales, which signals robust operational stability. However, the analysis flags a specific deficiency, as the company failed the test for Research and Development to Assets. This indicates that while JNJ's current financial health and valuation are compelling under this specific quantitative framework, its R&D investment relative to its asset base is below the model's ideal level for a growth-oriented company.

Key Decisions for Investors

• Investors with a quality-growth focus should view this high rating as a positive data point, as JNJ's financial profile aligns with an academically-backed model designed to identify 'winner' growth stocks.
• The failure on the 'Research and Development to Assets' metric must be scrutinized, as this could signal a potential long-term risk to the innovation pipeline, which is a critical growth driver in the biopharmaceutical sector.
• This report supports a fundamentally bullish case based on current financial stability and valuation, but investors should monitor JNJ's future R&D spending and pipeline developments to ensure the company's growth trajectory remains intact.